CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo M, Hernández-Sánchez M, Alonso-Pérez V, Rodríguez-Vicente AE, García-Tuñón I, Martín-Izquierdo M, Hernández-Sánchez JM, Herrero AB, Bastida JM, San Segundo L, Gruber M, García JL, Yin S, Ten Hacken E, Benito R, Ordóñez JL, Wu CJ, Hernández-Rivas JM.
Quijada-Álamo M, et al. Among authors: herrero ab.
Leukemia. 2020 Jun;34(6):1599-1612. doi: 10.1038/s41375-020-0714-3. Epub 2020 Jan 23.
Leukemia. 2020.
PMID: 31974435
Free PMC article.